Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers

Figure 1 Serum tumor markers in two groups of esophageal cancer patients. A: The research group had markedly lower CA125 levels than the control group after treatment; B: The research group had markedly lower MIP-3α levels than the control group after treatment. ^aP < 0.05 vs control; ^bP < 0.01, vs before treatment. CA125: Carbohydrate antigen 125; MIP-3α: Macrophage inflammatory protein-3α.

Figure 2 Angiogenesis-related indexes in two groups of esophageal cancer patients. A: The research group had markedly lower VEGF levels than the control group after treatment; B: The research group had markedly lower VEGFR-1 Levels than the control group after treatment; C: The research group had markedly lower bFGF levels than the control group after treatment; D: The research group had markedly lower Ang-2 levels than the control group after treatment. ^aP < 0.05 vs control; ^bP < 0.01, vs before treatment. VEGF: Vascular endothelial growth factor; VEGFR-1: Vascular endothelial growth factor receptor-1; bFGF: Basic fibroblast growth factor; Ang-2: Angiogenin-2.

Figure 3 Quality of life of esophageal cancer patients. A: The research group had markedly higher physical function scores than the control group after treatment; B: The research group had markedly higher role function scores than the control group after treatment; C: The research group had statistically higher emotional function scores than the control group after treatment; D: The research group had markedly higher social function scores than the control group after treatment; E: The research group had obviously higher cognitive function scores than the control group after treatment. ^bP < 0.01, vs before treatment.